- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01087645
A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects
February 24, 2017 updated by: Novo Nordisk A/S
Investigation of Safety, Tolerability and Bioavailability of NN9925 in Healthy Male Subjects
This trial is conducted in Europe.
The aim of this trial is to investigate the safety, tolerability and bioavailability (exploring absorption of drug in body) of NN9925 in healthy male subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nottingham, United Kingdom, NG11 6JS
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male subjects with good general health as judged by the physician
- Body weight of 65-95 kg (both inclusive)
- Body Mass Index (BMI) of 18.5-27.5 kg/m2 (both inclusive)
Exclusion Criteria:
- Known or suspected allergy to trial product or related products
- Acute infection or inflammation or other illness that may confound the results of the trial or pose a risk to the subject by administering the trial product, as judged by the physician
- Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) or malabsorptive states of disease (celiac disease, lactose intolerance or chronic pancreatitis), as judged by the physician
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trial part 1
|
Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels.
Progression to next dose will be based on safety evaluation
Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations.
The dose will be selected based on the results of part 1
Subjects will be randomised to receive a single dose of placebo
|
Experimental: Trial part 2
|
Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels.
Progression to next dose will be based on safety evaluation
Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations.
The dose will be selected based on the results of part 1
Subjects will be randomised to receive a single dose of placebo
As an active comparator, one standard dose will be given i.v.
(into the vein) at one study visit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and severity of adverse events (AEs) recorded
Time Frame: from dosing to Day 22
|
from dosing to Day 22
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The uptake in blood of oral NN9925
Time Frame: from 0 to 504 hours
|
from 0 to 504 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 12, 2010
Primary Completion (Actual)
September 16, 2010
Study Completion (Actual)
September 16, 2010
Study Registration Dates
First Submitted
March 12, 2010
First Submitted That Met QC Criteria
March 15, 2010
First Posted (Estimate)
March 16, 2010
Study Record Updates
Last Update Posted (Actual)
February 28, 2017
Last Update Submitted That Met QC Criteria
February 24, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9925-3779
- 2009-016975-31 (EudraCT Number)
- U1111-1113-2537 (Other Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on NN9925 (oral)
-
Université de MontréalSt. Justine's HospitalTerminatedObstructive Sleep ApneaCanada
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
Pulmagen TherapeuticsCompleted
-
Turning Point Therapeutics, Inc.RecruitingLymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS TumorsUnited States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
-
Mansoura UniversityCompletedSmall Bowel ObstructionEgypt
-
German Institute of Human NutritionLudwig-Maximilians - University of MunichCompletedDiabetes | Pre-diabetesGermany
-
Applied Molecular TransportActive, not recruitingUlcerative ColitisUnited States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
-
Brigham and Women's HospitalCompletedSleep Apnea, ObstructiveUnited States
-
WockhardtCompleted
-
Mayo ClinicNational Center for Advancing Translational Sciences (NCATS)Completed